



Message to the Arrhythmogenic Cardiomyopathy Community

LX2020 – Highlights from FY & 4Q 2025

Dear Advocacy Partners and PKP2-ACM community members,

We are pleased to share an [update](#) on LX2020, our investigational gene therapy for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM), based on highlights from Lexeo's full-year and fourth quarter 2025 update. Over the past year, we have continued to see encouraging clinical data from the ongoing LX2020 program.

Highlights include:

- In January 2026, Lexeo reported positive interim clinical data from the HEROIC PKP2 Phase 1/2 clinical trial evaluating LX2020 in individuals with PKP2-ACM. Clinical data was presented at the American College of Cardiology (ACC) Annual Meeting in March 2026, highlighting continued scientific and clinical interest in this investigational therapy.
- Heart tissue analyses (biopsies) showed dose dependent increases in PKP2 protein expression, vector copy number, and transgene mRNA in treated participants. These findings support that the gene therapy is delivering the intended genetic material to heart cells.
- Improvements in heart rhythm measures were observed, particularly in participants who received higher doses of LX2020. In these groups, the average burden of arrhythmias was reduced at the most recent follow-up visit, and most participants reported improvement in symptoms.
- LX2020 has been generally well tolerated across the ten participants treated to date, with no clinically significant complement activation (immune response) observed.

Next steps for the LX2020 program:

- Lexeo plans to provide a 12-month clinical data update for all participants in the higher dose cohorts in the fourth quarter of 2026.
- Engagement with the U.S. Food and Drug Administration (FDA) is expected in 2026 to discuss the LX2020 data and potential next steps for the program.

We are grateful to the individuals living with PKP2-ACM, their families, caregivers, investigators, and advocacy partners who make this research possible. We appreciate your continued partnership as we work to address the serious and unmet needs in arrhythmogenic cardiomyopathy.

The Lexeo Team